Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of -291.27% is 1161% below its 5-year average of -23.09%, near the low end of its 5-year range (-291.27%–32.91%).
718.10% below its 12-month average of -35.60%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 32.91%.
GROSS MARGIN
-291.27%
GROSS MARGIN AVG TTM
-35.60%
GROSS MARGIN AVG 3Y
-28.46%
GROSS MARGIN AVG 5Y
-23.09%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-718.10%
CURRENT VS 3Y AVG
-923.53%
CURRENT VS 5Y AVG
-1161.42%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
47.19%
median of 504 covered companies
CURRENT VS SECTOR MEDIAN
-717.29%
vs the sector median at left
Aclarion, Inc.
Market Cap
$6.74M
Gross Margin
-291.27%
TTM Avg
-35.60%
3Y Avg
-28.46%
5Y Avg
-23.09%
Market Cap
$6.76M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$6.72M
Gross Margin
80.62%
TTM Avg
90.31%
3Y Avg
-419.28%
5Y Avg
-4158.68%
Market Cap
$6.88M
Gross Margin
64.28%
TTM Avg
69.38%
3Y Avg
65.33%
5Y Avg
71.21%
Market Cap
$7.03M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
4.26%
5Y Avg
4.26%
Market Cap
$6.44M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$7.31M
Gross Margin
14.92%
TTM Avg
28.44%
3Y Avg
28.69%
5Y Avg
27.44%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aclarion, Inc. (ACON) | $6.74M | -291.27% | -35.60% | -28.46% | -23.09% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.76M | 0.00% | 0.00% | 0.00% | 0.00% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.72M | 80.62% | 90.31% | -419.28% | -4158.68% |
| Co-Diagnostics, Inc. (CODX)vs › | $6.88M | 64.28% | 69.38% | 65.33% | 71.21% |
| KALA BIO, Inc. (KALA)vs › | $7.01M | 0.00% | 0.00% | 8.55% | 24.65% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.03M | 0.00% | 0.00% | 4.26% | 4.26% |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.44M | 0.00% | 0.00% | 0.00% | 0.00% |
| Biomerica, Inc. (BMRA)vs › | $6.34M | 8.09% | 8.76% | 9.29% | 9.67% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | 14.92% | 28.44% | 28.69% | 27.44% |
| Femasys Inc. (FEMY)vs › | $6.10M | 61.96% | 64.25% | 64.10% | 65.91% |
Gross Margin
-291.3%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 32.91% |
| 2026-03-31 | -270.38% |
| 2025-12-31 | 9.69% |
| 2025-09-30 | 23.15% |
| 2025-06-30 | 26.61% |
| 2025-03-31 | -23.63% |
| 2024-12-31 | -100.90% |
| 2024-09-30 | -48.07% |
| 2024-06-30 | -112.32% |
| 2024-03-31 | -92.56% |
| 2023-12-31 | -40.73% |
| 2023-09-30 | -2.59% |
| 2023-06-30 | -13.06% |
| 2023-03-31 | 31.48% |
| 2022-12-31 | 23.23% |
| 2022-09-30 | 6.55% |
| 2022-06-30 | -33.47% |
| 2022-03-31 | -85.38% |
| 2021-12-31 | -35.43% |
| 2021-09-30 | -48.05% |
| 2021-06-30 | 20.75% |
| 2021-03-31 | -40.03% |
| 2020-12-31 | -63.89% |
| 2020-09-30 | 26.16% |
| 2020-06-30 | -103.90% |
| 2020-03-31 | -103.90% |
